A process is provided for the preparation of a compound of formulae (IA) (sidenafil) and (IB) ##STR1## comprising reacting a compound of formula (IIA) and (IIB) respectively in the presence of .sup.-- OR, wherein R in the case of formation of compound (IA) is CH.sub.2 CH.sub.3 and R in the case of formation of compound (IB) is CH.sub.2 CH.sub.2 CH.sub.3, where X is a leaving group: ##STR2##
Certain substituted sulfonamide derivatives of Formula I selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. ##STR00001##
Certain substituted benzamide derivatives of Formula I: ##STR1## selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
Certain substituted benzamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.
Pyrazole compounds represented by the formula: ##STR1## are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amyloid-.beta. mediated diseases and conditions.